![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, August 30, 2015 10:40:58 AM
Lets lay out all of the catalysts from now until Q1 of 2016. We got two phase 2a trials for SYN-004, phase 2a-1 trial results in September, phase 2a-2 results in December.
We have two phase 2 trials for SYN-010, phase 2-1 trial results in September, phase 2-2 results in December. Then my guess is fast track/QIDP status will be granted to SYN-004 if both phase 2a trials are positive. FDA is very desperate for a C-diff preventative or treatment (if I were them, I'd rather have the preventative), so they want to get SYN-004 to market as fast as possible. And we will also be getting SYN-004 phase 2b interim results in December.
My guess is we will get a Trimesta partner by end of 2015, as Liz and many others have mentioned, there is no timeline. No clue as to when we get the MRI data. But go look at post #975 written by Liz, and that will give you a good idea of what the MRI data will show.
We should also get an update on the P2A drug, which is currently being tested in a pig microbiome. Between all of those catalysts, I bet our pps will be somewhere in the 8-12 range. I don't think we will have to raise until at least Q2 of 2016, maybe later depending on the amount of funding from the Trimesta partner. The future for SYN is very bright, and if they have to dilute, so what? They are a small cap bios, get over it. All small cap bios have to dilute every now and then. As long as XON keeps taking shares as payment for the PKU, that is all I need to know to keep me invested. Here's to a good Fall and Winter for SYN, and I personally believe SYN will become one of the largest cap biotechs in the market over the next 15-20 years if they don't get gobbled up by a big pharma, you just have to be patient. Do your own DD, and don't let the bashers get to you. GLTAL
Recent TOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 11:30:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:10:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:05:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/16/2023 09:24:26 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2023 01:53:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2023 09:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:30:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 01:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 01:22:02 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM